Kolexia
Bouabdallah Kamal Biologie médicale
Bouabdallah Kamal
Biologie médicale
Hôpital Haut-lévêque
Pessac, France
152 Activités
17 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Maladie de Hodgkin Lymphome B Lymphome malin non hodgkinien Lymphome à cellules du manteau Récidive tumorale locale Lymphome folliculaire Lymphome B diffus à grandes cellules Lymphome T

Collaborateurs

Voir plus
Morschhauser Franck
Morschhauser Franck
Centre Hospitalier de Lille, Lille, France
Casasnovas Rene-Olivier
Casasnovas Rene-Olivier
Hôpital François Mitterrand, Dijon, France
Cartron Guillaume
Cartron Guillaume
Hôpital Saint-Éloi, Montpellier, France
Thieblemont Catherine
Thieblemont Catherine
Hôpital Saint-Louis, Paris, France

Industries

Voir plus
Takeda Pharmaceutical
26 collaboration(s)
Dernière en 2023
Gilead
19 collaboration(s)
Dernière en 2023
Janssen
13 collaboration(s)
Dernière en 2023
Sandoz
12 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
RELEVANCE: A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The "RELEVANCE" Trial (Rituximab Lenalidomide Versus ANy ChEmotherapy)is Being Conducted as Two Companion Studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the Combined Total of 1000 Patients Enrolled in Both Studies Will be Analyzed.
Essai Clinique (Celgene)   13 mars 2024
BRUIN-MCL-321: A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Essai Clinique (Loxo Oncology, Inc.)   24 janvier 2024
LOTIS 5: A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)
Essai Clinique (ADC Therapeutics S.A.)   23 janvier 2024
Study of Lacutamab in Peripheral T-cell Lymphoma: A Randomized Non Comparative Phase II Study of Lacutamab With GemOx Versus GemOx Alone in Relapsed/Refractory Patients With Peripheral T-cell Lymphoma
Essai Clinique (Innate Pharma)   04 décembre 2023
RELEVANCE: A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma
Essai Clinique (Celgene)   10 août 2023
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170): A Phase II Study of Pembrolizumab (MK-3475) in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS)
Essai Clinique (Merck & Co.)   25 juillet 2023
Transfusion needs after CD19 CAR T-cells for large B-cell lymphoma: Predictive factors and impact on outcome
Abstracts of the 33rd Regional Congress of the ISBT Gothenburg, Sweden 17–21 June 2023   12 juin 2023
Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Essai Clinique (Bayer)   12 juin 2023
Final safety and efficacy results of copanlisib monotherapy in patients with relapsed or refractory iNHL: 6-year follow-up of CHRONOS-1
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
Cell-free DNA sequencing allows the identification of the mutational profile of TFH lymphomas and has a predictive value: a LYSA study
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023